Tracking EGFR Mutant Resistance in a Large Cell Neuroendocrine Tumor of the Lung with Activating and Resistance EGFR Mutations Treated with Erlotinib-A Case Report and Literature Review

Abstract

In recent years, limited reports of epidermal growth factor receptor mutations in pulmonary large cell neuroendocrine tumors have implicated potential therapeutic targets in a tumor which has historically been treated with platinum based chemotherapy. We report partial response in metastatic large cell neuroendocrine tumor with an EGFR mutation. Moreover, targeted next generation sequencing analysis upon disease progression identified possible resistance pathways in EGFR and PIK3CA which parallels observations in adenocarcinoma of the lung. New therapeutic strategies may be need to be developed overcome resistance.